メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

経皮ドラッグデリバリ:医療機器のパイプライン評価

Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018

発行 GlobalData 商品コード 408769
出版日 ページ情報 英文 529 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.89円で換算しております。
Back to Top
経皮ドラッグデリバリ:医療機器のパイプライン評価 Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018
出版日: 2018年04月01日 ページ情報: 英文 529 Pages
概要

当レポートでは、世界の経皮ドラッグデリバリ市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 経皮ドラッグデリバリの概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 経皮ドラッグデリバリ:各企業で現在治験中のパイプライン製品

  • 経皮ドラッグデリバリの企業:治験段階別のパイプライン製品
  • 経皮ドラッグデリバリ:治験段階別のパイプライン製品

第5章 経皮ドラッグデリバリの企業・製品の概要

  • 3M Company
  • Aequus Pharmaceuticals Inc
  • Agile Therapeutics Inc
  • Allergan Plc
  • Alliqua BioMedical Inc
  • Altea Therapeutics Corporation (Inactive)
  • Anterios Inc
  • Apogee Technology Inc
  • Avro Life Sciences
  • Axxia Pharmaceuticals, LLC
  • Burke Pharmaceuticals LLC
  • Carbylan Therapeutics Inc
  • Cerimon Pharmaceuticals, Inc. (Inactive)
  • Corium International Inc
  • DBV Technologies SA
  • Dermisonics, Inc.
  • Dharma Therapeutics, Inc. (Inactive)
  • DURECT Corp
  • Echo Therapeutics Inc
  • Exploit Technologies Pte Ltd
  • Extend Biosciences Inc
  • EyeGate Pharmaceuticals Inc
  • Fe3 Medical Inc
  • FluGen Inc
  • French National Institute of Health and Medical Research
  • 久光製薬
  • ImmuPatch
  • Imperial College London
  • Indian Institute of Technology Bombay
  • Intercell AG (Inactive)
  • Interstitial NS
  • Isis Biopolymer, Inc.
  • Janisys
  • Massachusetts Institute of Technology
  • Meda AB
  • Medherant Ltd
  • メドレックス
  • mesoestetic USA Inc
  • Micropoint Technologies Pte Ltd
  • National Taiwan Ocean University
  • NeuroDerm Ltd
  • 日東電工
  • North Carolina State University
  • Novosanis NV
  • Nuvo Pharmaceuticals Inc
  • Old Dominion University
  • Pantec Biosolutions AG
  • Phosphagenics Ltd
  • Purdue University
  • Radius Health Inc
  • Ratio Inc
  • Scilex Ltd
  • Sensile Medical AG
  • Skinject Inc
  • ソレイジア・ファーマ
  • Sparsha Pharma International Pvt Ltd
  • Sparsha Pharma USA Inc
  • Stanford University
  • 大日本住友製薬
  • Syntropharma Ltd
  • 帝國製薬
  • tesa Labtec GmbH
  • Teva Pharmaceutical Industries Ltd
  • TheraJect Inc
  • TheraSolve NV
  • Theratech, Inc.
  • Titan Pharmaceuticals Inc
  • Transcu Group Limited (Inactive)
  • Transdermal Delivery Solutions Corp
  • TransPharma Medical Ltd
  • Transport Pharmaceuticals Inc
  • Univec, Inc. (Inactive)
  • University of Illinois at Chicago
  • University of Toronto
  • Vyteris, Inc. (Inactive)
  • Zambon Italia Srl
  • Z-Cube Srl
  • Zosano Pharma Corp
  • Zynerba Pharmaceuticals Inc

第6章 経皮ドラッグデリバリ市場:昨今の動向

第7章 付録

図表一覧

目次
Product Code: GDME0529EPD

GlobalData's Medical Devices sector report, "Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2018" provides an overview of Transdermal Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transdermal Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Transdermal Drug Delivery under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transdermal Drug Delivery and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transdermal Drug Delivery under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 10
  • 1.2 List of Figures 20

2 Introduction 21

  • 2.1 Transdermal Drug Delivery Overview 21

3 Products under Development 22

  • 3.1 Transdermal Drug Delivery - Pipeline Products by Stage of Development 22
  • 3.2 Transdermal Drug Delivery - Pipeline Products by Segment 23
  • 3.3 Transdermal Drug Delivery - Pipeline Products by Territory 24
  • 3.4 Transdermal Drug Delivery - Pipeline Products by Regulatory Path 25
  • 3.5 Transdermal Drug Delivery - Pipeline Products by Estimated Approval Date 26
  • 3.6 Transdermal Drug Delivery - Ongoing Clinical Trials 27

4 Transdermal Drug Delivery - Pipeline Products under Development by Companies 28

  • 4.1 Transdermal Drug Delivery Companies - Pipeline Products by Stage of Development 28
  • 4.2 Transdermal Drug Delivery - Pipeline Products by Stage of Development 32

5 Transdermal Drug Delivery Companies and Product Overview 37

  • 5.1 4P Therapeutics LLC Company Overview 37
  • 5.2 Actuated Medical Inc Company Overview 42
  • 5.3 Aequus Pharmaceuticals Inc Company Overview 43
  • 5.4 Agile Therapeutics Inc Company Overview 48
  • 5.5 Allergan Plc Company Overview 52
  • 5.6 Alliqua BioMedical Inc Company Overview 54
  • 5.7 Altea Therapeutics Corporation (Inactive) Company Overview 55
  • 5.8 AMW GmbH Company Overview 57
  • 5.9 AngioSoma Inc Company Overview 59
  • 5.10 Apogee Technology Inc Company Overview 60
  • 5.11 Apricus Biosciences Inc Company Overview 61
  • 5.12 Asahi Kasei Pharma Corp Company Overview 63
  • 5.13 AstraZeneca Plc Company Overview 64
  • 5.14 Avro Life Sciences Company Overview 67
  • 5.15 Burke Pharmaceuticals LLC Company Overview 68
  • 5.16 CB Scientific Inc. Company Overview 70
  • 5.17 Cerimon Pharmaceuticals, Inc. (Inactive) Company Overview 71
  • 5.18 Chrono Therapeutics Inc Company Overview 72
  • 5.19 Corium International Inc Company Overview 73
  • 5.20 DBV Technologies SA Company Overview 80
  • 5.21 DD Therapeutics LLC Company Overview 83
  • 5.22 Dermisonics Inc (Inactive) Company Overview 84
  • 5.23 Dharma Therapeutics, Inc. (Inactive) Company Overview 85
  • 5.24 Drexel University Company Overview 86
  • 5.25 DURECT Corp Company Overview 87
  • 5.26 Echo Therapeutics Inc Company Overview 88
  • 5.27 Emplicure AB Company Overview 89
  • 5.28 Endo International Plc Company Overview 91
  • 5.29 Extend Biosciences Inc Company Overview 92
  • 5.30 EyeGate Pharmaceuticals Inc Company Overview 93
  • 5.31 Fe3 Medical Inc Company Overview 96
  • 5.32 Hisamitsu Pharmaceutical Co Inc Company Overview 97
  • 5.33 ImmuPatch Company Overview 105
  • 5.34 Indian Institute of Science Company Overview 107
  • 5.35 Indian Institute of Technology Bombay Company Overview 108
  • 5.36 InMed Pharmaceuticals Inc Company Overview 109
  • 5.37 Institute of Materials Research & Engineering Company Overview 110
  • 5.38 Intercell AG (Inactive) Company Overview 111
  • 5.39 Interstitial NS Company Overview 112
  • 5.40 Isis Biopolymer, Inc. Company Overview 113
  • 5.41 Janisys Company Overview 117
  • 5.42 KTH Royal Institute of Technology Company Overview 118
  • 5.43 Kyowa Hakko Kirin Co Ltd Company Overview 119
  • 5.44 Lohmann Therapie-Systeme AG Company Overview 121
  • 5.45 Massachusetts Institute of Technology Company Overview 122
  • 5.46 Mayne Pharma Group Ltd Company Overview 123
  • 5.47 Medherant Ltd Company Overview 124
  • 5.48 MEDRx Co Ltd Company Overview 126
  • 5.49 MedRx, Inc. Company Overview 131
  • 5.50 Microdermics Inc Company Overview 132
  • 5.51 Micron Biomedical Inc Company Overview 133
  • 5.52 Micropoint Technologies Pte Ltd Company Overview 134
  • 5.53 Nemaura Pharma Ltd Company Overview 135
  • 5.54 NeuroDerm Ltd Company Overview 139
  • 5.55 Nitto Denko Corp Company Overview 141
  • 5.56 North Carolina State University Company Overview 144
  • 5.57 Noven Pharmaceuticals Inc Company Overview 146
  • 5.58 NutriBand Inc Company Overview 148
  • 5.59 Nuvo Pharmaceuticals Inc Company Overview 152
  • 5.60 Pain Therapeutics Inc Company Overview 153
  • 5.61 Phosphagenics Ltd Company Overview 154
  • 5.62 Prometheon Pharma LLC Company Overview 159
  • 5.63 Purdue University Company Overview 161
  • 5.64 Radius Health Inc Company Overview 162
  • 5.65 Scilex Ltd Company Overview 163
  • 5.66 Skinject Inc Company Overview 165
  • 5.67 Sparsha Pharma International Pvt Ltd Company Overview 166
  • 5.68 Sparsha Pharma USA Inc Company Overview 168
  • 5.69 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 169
  • 5.70 Stanford University Company Overview 170
  • 5.71 Sumitomo Dainippon Pharma Co Ltd Company Overview 171
  • 5.72 Syntropharma Ltd Company Overview 174
  • 5.73 Taho Pharmaceuticals Ltd Company Overview 176
  • 5.74 Teikoku Pharma USA Inc Company Overview 179
  • 5.75 tesa Labtec GmbH Company Overview 183
  • 5.76 Teva Pharmaceutical Industries Ltd Company Overview 185
  • 5.77 The Sheikh Zayed Institute for Pediatric Surgical Innovation Company Overview 186
  • 5.78 TheraJect Inc Company Overview 187
  • 5.79 TheraSolve NV Company Overview 189
  • 5.80 Theratech, Inc. Company Overview 190
  • 5.81 Titan Pharmaceuticals Inc Company Overview 191
  • 5.82 Transcu Group Limited (Inactive) Company Overview 195
  • 5.83 Transdermal Delivery Solutions Corp Company Overview 196
  • 5.84 Transdermal Specialties, Inc. Company Overview 199
  • 5.85 TransPharma Medical Ltd (Inactive) Company Overview 200
  • 5.86 Transport Pharmaceuticals Inc Company Overview 202
  • 5.87 TSRL Inc Company Overview 203
  • 5.88 Univec, Inc. (Inactive) Company Overview 204
  • 5.89 University of Illinois at Chicago Company Overview 207
  • 5.90 University of North Carolina at Chapel Hill Company Overview 208
  • 5.91 University of North Carolina at Chapel Hill School of Medicine Company Overview 209
  • 5.92 University of Toronto Company Overview 210
  • 5.93 ViiV Healthcare UK Ltd Company Overview 211
  • 5.94 Vyteris, Inc. (Inactive) Company Overview 212
  • 5.95 Xel Pharmaceuticals Inc Company Overview 213
  • 5.96 Zambon Italia Srl Company Overview 216
  • 5.97 Z-Cube Srl Company Overview 217
  • 5.98 Zosano Pharma Corp Company Overview 218
  • 5.99 Zynerba Pharmaceuticals Inc Company Overview 219

6 Transdermal Drug Delivery- Recent Developments 223

  • 6.1 Mar 12, 2018: Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS (abaloparatide) Injection 223
  • 6.2 Mar 12, 2018: Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 224
  • 6.3 Mar 12, 2018: Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update 225
  • 6.4 Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology 226
  • 6.5 Mar 07, 2018: Medherant expands team with appointment of David Davies as Head of Development 226
  • 6.6 Mar 07, 2018: FDA Confirms Date to Providing Regulatory Guidance for Aequus' Anti-Nausea Patch 227
  • 6.7 Mar 05, 2018: 3M Announces New Leadership Appointments 227
  • 6.8 Mar 02, 2018: Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine 228
  • 6.9 Mar 02, 2018: EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update 228
  • 6.10 Mar 01, 2018: DURECT Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs 230
  • 6.11 Mar 01, 2018: Purdue Pharma L.P. Names Dr. Marcelo Bigal as Chief Medical Officer 232
  • 6.12 Feb 28, 2018: Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain 233
  • 6.13 Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 234
  • 6.14 Feb 28, 2018: Syneos Health Reports Fourth Quarter and Full Year 2017 Results 236
  • 6.15 Feb 28, 2018: Agilent and Imperial College London Announce Collaboration Agreement 239
  • 6.16 Feb 28, 2018: Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care 240
  • 6.17 Feb 27, 2018: Hisamitsu Pharmaceutical Announces the Results of Phase III Clinical Study of HP-3000 in Japan 240
  • 6.18 Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 241
  • 6.19 Feb 23, 2018: GSK, Ministry of Economy, Trade and Industry "Superior Health and Good Management Act 2018 (White 500)" for 2 consecutive years certified 241
  • 6.20 Feb 23, 2018: Sumitomo Dainippon Pharma Names Hiroshi Nomura As President And CEO 242
  • 6.21 Feb 22, 2018: UCB Full Year Report 2017 243
  • 6.22 Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 243
  • 6.23 Feb 15, 2018: Camurus: Full year report 2017 244
  • 6.24 Feb 14, 2018: Sumitomo Dainippon Pharma and Nitto Announce Positive Topline Results from Phase 3 Study Evaluating Transdermal Patch Formulation of Atypical Antipsychotic LONASEN 246
  • 6.25 Feb 14, 2018: DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut 247
  • 6.26 Feb 13, 2018: Naltrexone transdermal patch (Nalsyn) has patent granted in USA 247
  • 6.27 Feb 08, 2018: Teva Reports 2017 Full Year and Fourth Quarter Financial Results 247
  • 6.28 Feb 08, 2018: Syneos Health Names Lisa van Capelle Chief Human Resources Officer 255
  • 6.29 Feb 08, 2018: Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights 256
  • 6.30 Feb 08, 2018: Syneos Health Names Lisa van Capelle Chief Human Resources Officer 257
  • 6.31 Feb 07, 2018: Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings 257
  • 6.32 Feb 07, 2018: GSK delivers improvements in sales, margins and cash flow in 2017 258
  • 6.33 Feb 06, 2018: Teva Pharmaceuticals laid off 46 employees in Parsippany 259
  • 6.34 Feb 05, 2018: EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery 259
  • 6.35 Feb 05, 2018: Allergan Appoints Matthew M. Walsh As Executive Vice President and Chief Financial Officer 260
  • 6.36 Feb 01, 2018: Japanese Pharmaceutical Company Agrees to 20 Year Settlement Agreement after Attempting to Block Generics 261
  • 6.37 Feb 01, 2018: Chrono Therapeutics Announces Appointment of David Happel as Chief Executive Officer 261
  • 6.38 Feb 01, 2018: Lannett Enters Into Consulting Agreement With Former CEO, Arthur Bedrosian 262
  • 6.39 Jan 31, 2018: Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch 262
  • 6.40 Jan 31, 2018: Notification of the Results of the Phase III Clinical Study of HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S. 263
  • 6.41 Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance 263
  • 6.42 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 270
  • 6.43 Jan 27, 2018: Prometheon Pharma Completes Pilot Study of Insulin Patch in Mini-Pigs 270
  • 6.44 Jan 25, 2018: 3M Reports Fourth-Quarter 2017 Results; Raises 2018 Earnings Outlook 270
  • 6.45 Jan 24, 2018: Solasia Pharma Announces Head Office Relocation 273
  • 6.46 Jan 19, 2018: Hisamitsu Pharmaceutical received Japan regulatory approval for ALLESAGA TAPE (HP-3060) , a transdermal system for the treatment of allergic rhinitis 273
  • 6.47 Jan 19, 2018: Teva Layoffs To Affect 65 Employees In Horsham, North Wales 274
  • 6.48 Jan 18, 2018: Lannett Appoints Timothy C. Crew As Board Of Directors 274
  • 6.49 Jan 09, 2018: Valeritas Appoints Joseph Saldanha as Chief Business Officer 274
  • 6.50 Jan 09, 2018: Representative Director and President of GlaxoSmithKline Corporation Personnel notice 275
  • 6.51 Jan 08, 2018: Allergan Provides 2018 Preliminary Financial Outlook for Select Income Statement Categories and Other Updates at 36th Annual J. P. Morgan Conference 275
  • 6.52 Jan 04, 2018: EyeGate Promotes Sarah Romano to Chief Financial Officer 276
  • 6.53 Jan 04, 2018: Generex CEO Provides 2017 Year-End Summary to Stakeholders 276
  • 6.54 Jan 03, 2018: Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update 280

7 Appendix 524

  • 7.1 Methodology 524
  • 7.2 About GlobalData 527
  • 7.3 Contact Us 527
  • 7.4 Disclaimer 527

List of Tables

1.1 List of Tables

  • Table 1: Transdermal Drug Delivery - Pipeline Products by Stage of Development 24
  • Table 2: Transdermal Drug Delivery - Pipeline Products by Segment 25
  • Table 3: Transdermal Drug Delivery - Pipeline Products by Territory 26
  • Table 4: Transdermal Drug Delivery - Pipeline Products by Regulatory Path 27
  • Table 5: Transdermal Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Table 6: Transdermal Drug Delivery - Ongoing Clinical Trials 29
  • Table 7: Transdermal Drug Delivery Companies - Pipeline Products by Stage of Development 30
  • Table 8: Transdermal Drug Delivery - Pipeline Products by Stage of Development 34
  • Table 9: 4P Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 10: Passive Transdermal Clonidine Patch - Product Status 39
  • Table 11: Passive Transdermal Clonidine Patch - Product Description 39
  • Table 12: Passive Transdermal Fentanyl Patch - Product Status 40
  • Table 13: Passive Transdermal Fentanyl Patch - Product Description 40
  • Table 14: Passive Transdermal Lidocaine Patch - Product Status 40
  • Table 15: Passive Transdermal Lidocaine Patch - Product Description 40
  • Table 16: Passive Transdermal Patch - Product Status 41
  • Table 17: Passive Transdermal Patch - Product Description 41
  • Table 18: Passive Transdermal Scopalamine Patch - Product Status 41
  • Table 19: Passive Transdermal Scopalamine Patch - Product Description 41
  • Table 20: Transdermal Apomorphine Patch - Product Status 42
  • Table 21: Transdermal Apomorphine Patch - Product Description 42
  • Table 22: Transdermal Exenatide Patch - Product Status 42
  • Table 23: Transdermal Exenatide Patch - Product Description 42
  • Table 24: Transdermal FSH Patch - Product Status 43
  • Table 25: Transdermal FSH Patch - Product Description 43
  • Table 26: Transdermal Patch - Diabetes - Product Status 43
  • Table 27: Transdermal Patch - Diabetes - Product Description 43
  • Table 28: Actuated Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 29: GentleDispense System - Product Status 44
  • Table 30: GentleDispense System - Product Description 44
  • Table 31: Aequus Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 32: AQS1301 - Product Status 45
  • Table 33: AQS1301 - Product Description 45
  • Table 34: AQS1302 - Product Status 46
  • Table 35: AQS1302 - Product Description 46
  • Table 36: AQS1303 - Product Status 46
  • Table 37: AQS1303 - Product Description 47
  • Table 38: AQS1304 - Product Status 47
  • Table 39: AQS1304 - Product Description 47
  • Table 40: Aequus Pharmaceuticals Inc - Ongoing Clinical Trials Overview 48
  • Table 41: AQS1301 - Phase Ia Study of AQS-1301 in Healthy Subjects 49
  • Table 42: Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 43: AG200-ER Patch - Product Status 50
  • Table 44: AG200-ER Patch - Product Description 51
  • Table 45: AG200-SP Patch - Product Status 51
  • Table 46: AG200-SP Patch - Product Description 51
  • Table 47: AG890 Patch - Product Status 52
  • Table 48: AG890 Patch - Product Description 52
  • Table 49: Twirla (AG200-15) - Product Status 52
  • Table 50: Twirla (AG200-15) - Product Description 53
  • Table 51: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 52: Nanotechnology-Based Transdermal Delivery System - Product Status 54
  • Table 53: Nanotechnology-Based Transdermal Delivery System - Product Description 54
  • Table 54: Norethindrone Transdermal Delivery System - Product Status 55
  • Table 55: Norethindrone Transdermal Delivery System - Product Description 55
  • Table 56: Alliqua BioMedical Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 57: PHN Patch - Product Status 56
  • Table 58: PHN Patch - Product Description 56
  • Table 59: Altea Therapeutics Corporation (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 60: Transdermal Enoxaparin Sodium Patch - Product Status 57
  • Table 61: Transdermal Enoxaparin Sodium Patch - Product Description 57
  • Table 62: Transdermal Fentanyl Citrate Patch - Product Status 58
  • Table 63: Transdermal Fentanyl Citrate Patch - Product Description 58
  • Table 64: Transdermal Protein Patch - Product Status 58
  • Table 65: Transdermal Protein Patch - Product Description 58
  • Table 66: AMW GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 67: Anastrozole Transdermal Patch - Product Status 59
  • Table 68: Anastrozole Transdermal Patch - Product Description 59
  • Table 69: Rotigotine Patch - Product Status 60
  • Table 70: Rotigotine Patch - Product Description 60
  • Table 71: AngioSoma Inc Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 72: Transdermal PGE-1 Patch - Product Status 61
  • Table 73: Transdermal PGE-1 Patch - Product Description 61
  • Table 74: Apogee Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 75: PyraDerm - Product Status 62
  • Table 76: PyraDerm - Product Description 62
  • Table 77: Apricus Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 78: Second Generation Vitaros Room Temperature Device - Product Status 63
  • Table 79: Second Generation Vitaros Room Temperature Device - Product Description 63
  • Table 80: Vitaros - Product Status 64
  • Table 81: Vitaros - Product Description 64
  • Table 82: Asahi Kasei Pharma Corp Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 83: Teribone Microneedle Patch System - Product Status 65
  • Table 84: Teribone Microneedle Patch System - Product Description 65
  • Table 85: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 86: EMLA Patch - Product Status 66
  • Table 87: EMLA Patch - Product Description 66
  • Table 88: AstraZeneca Plc - Ongoing Clinical Trials Overview 67
  • Table 89: EMLA Patch - Peripheral Intravenous Cannulation in Children with Difficult Vein Access: Randomized Study Comparing Accuvein 400 versus Standard Care 68
  • Table 90: Avro Life Sciences Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 91: Transdermal Drug Delivery Patch - Product Status 69
  • Table 92: Transdermal Drug Delivery Patch - Product Description 69
  • Table 93: Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 94: BLU402 Hydrogel Patch Wart Kit - Product Status 70
  • Table 95: BLU402 Hydrogel Patch Wart Kit - Product Description 70
  • Table 96: Drug Delivery Patch - Product Status 71
  • Table 97: Drug Delivery Patch - Product Description 71
  • Table 98: CB Scientific Inc. Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 99: Pain-Patch - Product Status 72
  • Table 100: Pain-Patch - Product Description 72
  • Table 101: Cerimon Pharmaceuticals, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 102: Topical Diclofenac Patch - Product Status 73
  • Table 103: Topical Diclofenac Patch - Product Description 73
  • Table 104: Chrono Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 105: Biologically-Timed Drug Delivery Device - Product Status 74
  • Table 106: Biologically-Timed Drug Delivery Device - Product Description 74
  • Table 107: Corium International Inc Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 108: Corplex Donepezil Transdermal System - Product Status 75
  • Table 109: Corplex Donepezil Transdermal System - Product Description 76

List of Figures

1.2 List of Figures

  • Figure 1: Transdermal Drug Delivery - Pipeline Products by Stage of Development 24
  • Figure 2: Transdermal Drug Delivery - Pipeline Products by Segment 25
  • Figure 3: Transdermal Drug Delivery - Pipeline Products by Territory 26
  • Figure 4: Transdermal Drug Delivery - Pipeline Products by Regulatory Path 27
  • Figure 5: Transdermal Drug Delivery - Pipeline Products by Estimated Approval Date 28
  • Figure 6: Transdermal Drug Delivery - Ongoing Clinical Trials 29
Back to Top